Company
UCB
UCB has 31 drugs tracked on RxWires: 6 post-market, 2 approved, 11 in Phase 3, 5 in Phase 2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| levetiracetam | Post-Market | Epilepsy, Partial |
| Rozanolixizumab | Post-Market | Myasthenia Gravis |
| Lab Work | Post-Market | Rheumatoid Arthritis |
| Certolizumab pegol | Post-Market | Rheumatoid Arthritis |
| Lacosamide | Post-Market | Partial Epilepsy |
| Levocetirizine dihydrochloride | Post-Market | Rhinitis |
| DIETHYLPROPION HYDROCHLORIDE | Approved | |
| CORSYM | Approved | |
| fenfluramine | Phase 3 | Dravet Syndrome |
| Rotigotine | Phase 3 | Restless Legs Syndrome |
| Keppra XR (Levetiracetam XR) | Phase 3 | Epilepsy |
| Bimekizumab | Phase 3 | Axial Spondyloarthritis |
| Staccato alprazolam | Phase 3 | Stereotypical Prolonged Seizures |
| DZP | Phase 3 | Systemic Lupus Erythematosus |
| Dapirolizumab pegol | Phase 3 | Systemic Lupus Erythematosus |
| zilucoplan (RA101495) | Phase 3 | Generalized Myasthenia Gravis |
| Brivaracetam | Phase 3 | Childhood Absence Epilepsy |
| Alprostadil (Prostaglandin E1) | Phase 3 | Stage II Peripheral Arterial Occlusive Disease |
| Rotigotine 1 milligram/24 hours | Phase 3 | Restless Legs Syndrome |
| Minzasolmin (UCB0599) | Phase 2 | Parkinson's Disease |
| Galvokimig | Phase 2 | Chronic Obstructive Pulmonary Disease With Chronic Bronchitis |
| Epratuzumab | Phase 2 | Systemic Lupus Erythematosus |
| Bepranemab | Phase 2 | Alzheimer's Disease |
| SPM927/Lacosamide | Phase 2 | Painful Diabetic Neuropathy |
| Bimekizumab regimen 1 iv | Phase 1 | Psoriatic Arthritis |
| Rotigotine PR 2.1.4 | Phase 1 | Healthy Volunteers |
| UCB7665 Intravenous 1 | Phase 1 | Healthy |
| CDP6038 | Phase 1 | Healthy Volunteers |
| Padsevonil | Phase 1 | Healthy Study Participants |
| Rotigotine transdermal patch | Phase 1 | Parkinson's Disease |
| NPT200-11 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow UCB on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.